P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement

• Published in: Pharmacological research Vol. 48; no. 4; pp. 347 - 359
• Main Authors: Varma, Manthena V.S, Ashokraj, Yasvanth, Dey, Chinmoy S, Panchagnula, Ramesh
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.10.2003
• Subjects: Animals; ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors; ATP-Binding Cassette, Sub-Family B, Member 1 - chemistry; ATP-Binding Cassette, Sub-Family B, Member 1 - pharmacokinetics; Biological Availability; Biological Transport - drug effects; Biological Transport - physiology; Drug Evaluation, Preclinical - methods; Inhibitors; Intestinal Absorption - drug effects; Intestinal Absorption - physiology; Intestinal permeability; Models, Biological; P-glycoprotein; Peroral drug delivery; Pharmacokinetic optimization; Screening; P-gp; SAR; Peroral drug delivery; Intestinal permeability; ADP; P-glycoprotein; Screening; GIT; Inhibitors; Pharmacokinetic optimization; MDR; CYP; ATP; PET
• ISSN: 1043-6618; 1096-1186
• DOI: 10.1016/S1043-6618(03)00158-0

Drug efflux pumps like P-glycoprotein (P-gp) and multidrug resistance (MDR) proteins were recognized to posses functional role in determining the pharmacokinetics of drugs administered by peroral as well as parenteral route. Advancements in molecular biology, to some extent, had revealed the structure, localization and functional role of P-glycoprotein and its mechanism of drug efflux. Broad substrate recognization by this protein and clinical implications of its inhibition has revolutionized cancer chemotherapy leading to design and development of novel P-glycoprotein inhibitors. In the recent times, the application of these inhibitors in improving peroral drug delivery has gained special interest. Inhibition of P-glycoprotein improves intestinal absorption and tissue distribution while reducing the substrate metabolism and its elimination. Eventually, various screening methodologies have been developed for determining the activity of P-glycoprotein, kinetics of drug transport and identification of substrates and inhibitors. In the present review, techniques used for screening P-glycoprotein inhibitors and the scope of these inhibitors in optimizing peroral drug absorption and pharmacokinetics are discussed along with a brief introduction to P-glycoprotein, its physiological function and active role in extrusion of drugs.